The prices of generic drugs are declining as more of them are becoming available on the market along with pressure from major retail pharmacies.
It is just not going to get better anytime soon.
Teva's stock is crumbling as another analyst slams it with a downgrade.
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
The deal is worth $1.4 billion and PharMerica's board has already given it the green light.